"name","description","uuid:ID","instanceType","id","label","rationale"
"Study Design 1","The main design for the study","28197bb6-6488-4733-b586-88daa92fb764","StudyDesign","StudyDesign_1","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
